期刊
VACCINE
卷 28, 期 45, 页码 7248-7255出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.09.021
关键词
H1N1 vaccines; Vaccine safety; Post-marketing surveillance
资金
- CDC
- FDA
The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (similar to 10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barre syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered). Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据